POLICYBZR — earnings call

The transcript as filed. Every paragraph is addressable: its link names the page and the position it sits at in the call.

Prepared remarks

Sachin Salgaonkar: · Okay, sure. So, second question, again, wanted to understand, some

Thanks, Mohit.

Hi, management.

Congratulations on a great set of numbers.

I have three questions.

First question is about the QIP announcement.

Would love to understand how management is thinking in terms of investments, particularly on the lines of international markets, and which area could be of interest for you guys from an international market point of view?

Okay, sure.

So, second question, again, wanted to understand, some impact, or, if management could give a clarity in terms of impact from transitioning towards a COR-based model for health and term.

I understand the impact will be seen in subsequent quarters on the P&L.

Anything you guys could help in terms of allowing us to model that properly would be helpful, so that's the second question.

And third question, wanted to understand, generally, how the premium growth has been since the quarter, because part of a growth in the last quarter was largely driven on expectations of a price increase in premiums.

So, something changed out there, from an expectation point of view?

And Yashish would love to understand your thoughts on multiple media articles which talk about potential commission cuts happening in the sector.

Thanks.

Thanks, guys.

Just maybe one quick follow-up out here.

You see, typically we've found Indian companies going out of India in search of growth when the growth in the core market starts slowing down.

But for you guys, it's the opposite.

If anything, the growth in India is accelerating, and clearly there is a huge runway from a growth point of view.

I was just trying to understand, is it something really great in an international market that makes you guys look at an international market?

Or is it just that, whatever you guys are looking to do in India, trying to replicate that in other markets?

What is that area of expertise which you guys have been looking to bring into the international market?

Alright, very clear.

Thanks a lot.

Hi, Yashish & team, congratulations on a great set of results again.

My first question is on the growth, basically, on Core insurance side, new business premium.

Obviously, you have highlighted the reasons why you should get the growth, but if we try to look into these contours of this growth, where is it coming from?

Because most of the industry data does talk about a much lower growth, some of the partners who work with you more closely have grown faster, but still, probably half of what you have grown at.

So, can you give more color on what is happening?

How are you driving this growth?

Right, thanks for that.

My second question is on the commissions that we are effectively getting.

Let me know if I'm doing the wrong math.

So, if I'm looking at your business YOY, health and term, which are probably the highest commission product in year one, have grown fastest.

So ideally, it should have gone up.

In this quarter in particular, your new business premium has also grown at almost a similar rate to renewal.

So, again, don't see any dilution from that.

Still, they were roughly flat.

Are we reading too much into it, or as Yashish used to mention in earlier calls that this is more of a quarterly thing?

Got it.

Thanks for the clarity, Yashish there.

My final question is on the size of this potential QIP that we are looking at.

We already have ₹5,000 odd Cr of cash and we are looking to add more.

Are we looking at, something very sizable, or this is more of multiple acquisitions that you're looking at?

Sure, sure, alright.

Thank you and all the best.